We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Features of Rituximab-Induced Killing of B Lymphocytes.
- Authors
Youinou, P.; Mankaï, A.; Bordron, A.; Berthou, C.
- Abstract
The author reflects on the Rituximab-induced killing of B lymphocytes which includes the therapeutic use of Rituximab (RTX) and anti-B lymphocyte antibodies (Abs). RTX was approved by the Food and Drug Administration for the treatment of low grade and follicular non-Hodgkin's lymphoma (NHL). He emphasized that the efficacy of RTX may be lessened when the pathogenesis is affected by the survival of B cell lymphopenia. An overview of RTX mechanism is also presented.
- Subjects
RITUXIMAB; LYMPHOMA treatment; ALTERNATIVE treatment for cancer; IMMUNOGLOBULINS; CARCINOGENESIS
- Publication
Scandinavian Journal of Immunology, 2008, Vol 68, Issue 2, p118
- ISSN
0300-9475
- Publication type
Editorial
- DOI
10.1111/j.1365-3083.2008.02132.x